SURMOUNT-1Tirzepatide Once Weekly for Weight Management in Obesity or Overweight with Comorbidities

This clinical trial focuses on the effectiveness and safety of a once-weekly drug called Tirzepatide in individuals without type 2 diabetes who are either obese or overweight and have health conditions related to their weight. The study's primary goal is to help these individuals manage their weight and potentially delay or prevent the onset of type 2 diabetes. Participants who have prediabetes at the start of the study can continue the treatment for a longer period to assess long-term weight management benefits. This research is crucial as it aims to provide a new treatment option for weight management and address the challenge of obesity-related health conditions. During the trial, participants are randomly assigned to receive one of four treatments: Tirzepatide in doses of 5 mg, 10 mg, 15 mg, or a placebo, which is a substance with no therapeutic effect. The drug is administered once a week via a subcutaneous injection using an autoinjector. All participants also receive lifestyle counseling that emphasizes a reduced-calorie diet and increased physical activity. The main treatment period lasts for 72 weeks. The study measures the mean percentage change in body weight from the start of the treatment and the percentage of participants who achieve a body weight reduction of 5% or more. Safety is monitored throughout the study, including any adverse events and laboratory testing.